Callidus Software Inc. (NASDAQ:CALD) announced that it has partnered with Mapping Analytics, the creator of the ProAlign® Sales Territory Alignment and Optimization solution. The agreement was signed in the second quarter of 2011. "Maximizing market coverage is essential to maximizing sales performance," said Lorna Heynike, Senior Vice President, Marketing, Callidus Software. "This partnership with Mapping Analytics will enable Callidus to extend the Monaco On Demand SPM suite's class-leading territory management capabilities with a powerful mapping visualization solution that promotes territory alignment across regions.
Callidus Software Inc. provides sales performance management (SPM) software and services. Its SPM systems are used to monitor and analyze sales performance and incentive compensation management programs.
Power3 Medical Products, Inc. (PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Symptom of breast cancer:
swelling of all or part of the breast
skin irritation or dimpling
redness, scaliness, or thickening of the breast skin
a lump in the underarm area
BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the Power3 Medical Products' patient database. Statistical analysis by linear discriminate function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
Please visit Power3 Medical Products, Inc website http://www.power3medical.com.
TAT Technologies Ltd. (NASDAQ:TATT) announced it signed a Settlement Agreement with First Aviation Services Inc. ("FAvS"). On December 4, 2009, TAT's indirect subsidiary, Piedmont Aviation Component Services, LLC ("Piedmont"), acquired 5,766,667 Class B Common shares of FAvS, representing 37% of FAvS's then share capital and on a diluted basis and $750,000 of FAvS Preferred Shares (entitling Piedmont to cash dividends at an annual rate of 12% payable quarterly or at the discretion of FAvS to PIK dividends payable in additional Preferred Shares at an annual rate of 15%).
TAT Technologies Ltd., together with its subsidiaries, provides various products and services to the commercial and military aerospace and ground defense industries in the United States, Europe, the Middle East, Asia, and South America.
MedAssets (NASDAQ:MDAS) announced the introduction of the MedAssets Bundled Payment Solution-a groundbreaking addition to its broad portfolio of technology products in health information solution and services. The Bundled Payment Solution delivers to market the first reimbursement system specifically designed to manage and transact episode of care payments. Featuring a unique capability to bundle services adjusted for risk/severity at the patient level, the Web-based technology intakes the user's current fee-for-service claims data and groups it into a "bundle" based on industry-standard quality benchmarks. User's current fee-for-service claims data and groups it into a "bundle" based on industry-standard quality benchmarks.
MedAssets, Inc. provides technology enabled products and services for hospitals, health systems, and ancillary healthcare providers in the United States.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).